{"schema_version":"secwatch.filing_event.v1","accession":"0001129928-26-000057","form_type":"8-K","ticker":"ONCY","cik":"0001129928","company_name":"ONCOLYTICS BIOTECH INC","filed_at":"2026-09-28T13:32:06+00:00","discovered_at":"2026-09-28T13:34:04.535639+00:00","generated_at":"2026-10-12T13:33:05.729794+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Oncolytics: REO 033 CRC study sites nearly all activated; interim Part A data due year-end 2026","bullets":["Part A of randomized REO 033 to enroll ~60 patients with second-line RAS-mutant MSS metastatic colorectal cancer; ORR is primary endpoint, with PFS, OS, safety and biomarkers.","Interim Part A data expected by year-end 2026, based on number of evaluable patients enrolled by end of October; multiple patients now on study.","REO 022 prior data: ORR 33% vs ~6-11% historical benchmark; median PFS 16.6 months vs ~5.7; median OS 27.0 months vs ~11.2; median duration of response 19.5 months.","FDA alignment on pivotal Part B expansion: potential accelerated approval on objective response rate; progression-free survival basis for full approval; Part A data to inform Part B.","RO 033 tests pelareorep plus FOLFIRI and bevacizumab versus FOLFIRI and bevacizumab; COO John McAdory cites strong enrollment momentum."],"urls":{"canonical":"https://secwatch.observer/filing/0001129928-26-000057","json":"https://secwatch.observer/filing/0001129928-26-000057.json","markdown":"https://secwatch.observer/filing/0001129928-26-000057.md","text":"https://secwatch.observer/filing/0001129928-26-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000057/0001129928-26-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000057/oncy-20260928.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:33:05.729794+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}